{
    "2019-02-11": [
        [
            {
                "time": "2018-01-31",
                "original_text": "Here's Why Coherus BioSciences Rose 48.7% in January",
                "features": {
                    "keywords": [
                        "Coherus",
                        "BioSciences",
                        "Rose",
                        "January"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-31",
                "original_text": "5 High-Growth Stocks Undervalued by the Market",
                "features": {
                    "keywords": [
                        "High-Growth",
                        "Stocks",
                        "Undervalued",
                        "Market"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-31",
                "original_text": "Here's Why Coherus BioSciences Rose 48.7% in January",
                "features": {
                    "keywords": [
                        "Coherus",
                        "BioSciences",
                        "Rose",
                        "January"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-31",
                "original_text": "IWV, PEP, ABBV, AMGN: ETF Outflow Alert",
                "features": {
                    "keywords": [
                        "IWV",
                        "PEP",
                        "ABBV",
                        "AMGN",
                        "ETF",
                        "Outflow"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance",
                        "consumer goods",
                        "pharmaceuticals",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-31",
                "original_text": "AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Teneobio",
                        "Strategic",
                        "Transaction",
                        "Multiple Myeloma"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2018-01-31",
                "original_text": "ABBV or CELG: Comparing Dividends, Interest Expenses, and Debt",
                "features": {
                    "keywords": [
                        "ABBV",
                        "CELG",
                        "Dividends",
                        "Interest Expenses",
                        "Debt"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}